Balchem Corp. Q1 2011 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011. Balchem Corporation develops, manufactures, and distributes specialty performance ingredients for food, nutritional, pharmaceutical, animal health, medical device sterilization, and oil and gas industries. The company operates through three segments: Specialty Products, Food, Pharma & Nutrition, and Animal Nutrition & Health.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Net Sales | $73,008 | $59,903 |
| Gross Margin | $20,780 (28.5%) | $17,414 (29.1%) |
| Operating Income | $13,298 | $10,494 |
| Net Earnings | $8,912 | $7,029 |
| Diluted EPS | $0.30 | $0.24 |
| Cash from Operations | $9,671 | $9,697 |
| Cash and Equivalents (End of Period) | $82,052 | $51,361 |
| Total Debt (Current + Long-term) | $4,826 | $4,914 |
Note: All dollar amounts in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21.9% year-over-year, driven by volume growth across all segments. The Animal Nutrition & Health segment saw the largest increase (25.9%), fueled by higher sales of choline products and industrial derivatives.
- Margin Pressure: While gross margin dollars increased 19.3%, the gross margin percentage declined slightly from 29.1% to 28.5%. This was attributed to higher raw material costs (specifically petro-chemicals) and operating inefficiencies at one plant.
- Profitability: Net earnings rose 26.8% to $8.9 million. Operating expenses increased 8.1% due to the Aberco acquisition, increased headcount, and consultancy fees, but remained lower as a percentage of sales (10.2% vs 11.6% prior year).
- Liquidity: Cash and cash equivalents increased by $4.8 million to $82.1 million. Working capital improved to $111.4 million.
Outlook, Risks, and Contingencies
- Outlook: Management continues to focus on volume growth through new product launches in domestic and international markets. The company is actively pursuing additional acquisition candidates.
- Debt Facilities: The company maintains a European Term Loan (maturity May 2014) and two revolving credit facilities (European and U.S.) maturing in May 2011. Management expects these facilities to be renewed in the normal course of business. No amounts were outstanding on the revolving facilities as of March 31, 2011.
- Environmental Contingencies: The company is involved in ongoing discussions with the NYDEC regarding a remediation site in Slate Hill, NY, though monitoring costs have been minimal. The Verona, MO facility (a former Superfund site) is indemnified by the prior owner for potential liabilities.
- Market Risks: The company is exposed to foreign currency exchange rate fluctuations and commodity price risks for raw materials. A 100 basis point change in interest rates would impact annual interest expense by approximately $48,000.
Investor Verification Checklist
- Verify the sustainability of the 21.9% sales growth given the noted operating inefficiencies at one plant.
- Monitor the renewal status of the revolving credit facilities maturing in May 2011.
- Track raw material cost trends, particularly petro-chemicals, to assess future gross margin stability.
- Review the integration progress and cost impact of the Aberco acquisition.
- Confirm the status of the environmental remediation discussions with NYDEC and the indemnification coverage for the Verona, MO site.